2017 News Releases

Webcast ImageWebcast
Clearside Biomedical Inc at the 16th Annual Needham Healthcare Conference (Live)
04/04/17 at 11:20 a.m. ET
Clearside Biomedical Inc at the 16th Annual Needham Healthcare Conference
Tuesday, April 4, 2017 11:20 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
03/28/17Clearside Biomedical, Inc. to Present at the 16th Annual Needham Healthcare Conference
ALPHARETTA, Ga., March 28, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that its Chief Executive Officer and President, Daniel H. White, will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017 at 11:20 a.m. ET at the Westin NY Grand Central Hotel in New York, NY. A live webcast of the presentation can be acce... 
Printer Friendly Version
03/14/17Clearside Biomedical, Inc. Announces Fourth Quarter And Full Year 2016 Financial Results
ALPHARETTA, Ga., March 14, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial results for the fourth quarter and full year ended December 31, 2016, and provided an update on its development programs. “2016 was truly an historic year for Clearside in our pursuit of transformative, elegant, precise solutions to restore and preserve vision,... 
Printer Friendly Version
03/07/17Clearside Biomedical, Inc. to Report Fourth Quarter and Full Year 2016 Financial Results on March 14, 2017 – Conference Call to Follow
ALPHARETTA, Ga., March 07, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) (“Clearside” or the “Company”), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that its fourth quarter and full year 2016 financial results will be released at 7:00 a.m. on Tuesday, March 14, 2017. Following the release, Clearside will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s fina... 
Printer Friendly Version
03/01/17Clearside Biomedical, Inc. to Present at the Cowen and Company 37th Annual Health Care Conference
ALPHARETTA, Ga., March 01, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that its Chief Executive Officer and President, Daniel H. White, will present at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017 at 9:20 a.m. ET at the Boston Marriott Copley Place in Boston, MA. A live webcast of the presentation can ... 
Printer Friendly Version
03/01/17Clearside Biomedical, Inc. Receives Notice of Allowance for Ninth U.S. Patent
ALPHARETTA, Ga., March 01, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Number 15/001,610 entitled, “Methods and Devices for the Treatment of Ocular Diseases in Human Subjects.” Once the administrative process is complete, the U.S. Pa... 
Printer Friendly Version
02/27/17Clearside Biomedical, Inc. Redirects Pre-Clinical AMD Research Resources Toward Ongoing DME Clinical Development Program
ALPHARETTA, Ga., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it has initiated a strategic realignment of its research and development resources from its pre-clinical development program for axitinib for the treatment of wet age-related macular degeneration (“wet AMD”) toward its ongoing clinical development program for the treat... 
Printer Friendly Version
02/16/17Clearside Biomedical, Inc. Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata™ Used Together With Eylea in Subjects With Retinal Vein Occlusion
ALPHARETTA, Ga., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the enrollment of the first patient in a Phase 3 clinical trial (“SAPPHIRE”) of Zuprata™, its proprietary suspension formulation of the corticosteroid triamcinolone acetonide, used together with EYLEA® (aflibercept) for the treatment of macular edema associated with retinal... 
Printer Friendly Version
01/05/17Clearside Biomedical, Inc. Receives Notice of Allowance for Seventh U.S. Patent
ALPHARETTA, Ga., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Number 15/086,485 entitled, “Methods and Devices for the Treatment of Ocular Diseases in Human Subjects.” Once the administrative process is complete, the U.S. Pat... 
Printer Friendly Version
01/05/17Clearside Biomedical, Inc. to Present at J.P. Morgan Healthcare Conference
ALPHARETTA, Ga., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that Daniel H. White, Chief Executive Officer and President of Clearside, will present at the 35th Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2017 at 7:30am PST, at the Westin St. Francis Hotel, in San Francisco, California. The presentation will b... 
Printer Friendly Version
01/04/17Clearside Biomedical, Inc. Appoints Richard Beckman, M.D., as Chief Medical Officer
ALPHARETTA, Ga., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the appointment of Richard L. Beckman, M.D. to the position of Chief Medical Officer. Dr. Beckman is a board certified ophthalmologist who brings 13 years of clinical practice experience and over 20 years of corporate executive and consultancy experience within the globa... 
Printer Friendly Version